Updates from 2017-2018 Francesca Incardona Arevir meeting 2018 - - PowerPoint PPT Presentation

Updates from 2017-2018

Francesca Incardona

Arevir meeting 2018

KRG-DHIS2 project

• EuResist is partner together with I-PRO of

the project led by University of Rome Tor Vergata, funded by Italian cooperation, to set up a System of Health Monitoring and Surveillance activities in the Autonomous Region of Kurdistan.

AMS (ARCA Mentor School) 2017

• EuResist supported I-PRO and University of

Siena in the organisation of the 3rd hands-

• n training on db querying for young

clinicians and biologists

• The course was very successful: 4

abstracts accepted at ICAR, 3 abstracts accepted at European Resistance meeting

The EuResist Mentor School

The program is divided in two phases: a face to face intensive session, and a 9/ 12- months remote follow-up phase.

• The on-site programme was held in

Cologne… yesterday!

• Highly interactive: 8 hours of practice in

small groups led by a medical trainer and a IT/ statistical trainer. Queries run on the EIDB.

• In the follow-up, remote phase, the queries

will be refined, data analysed, results discussed and possibly prepared for publications

The EuResist Mentor School

The EuResist Mentor School

The two queries:

• “Does resistance to nukes influence

resistance to first line INSTIs?”

• “Efficacy of dual regimen as switch in

patients with undetectable VL, including influence of previous resistance”

INTegrating Euresist Data base with intEGrase Resistance data for optimized Antiretroviral TrEatment

• Started in March 2017
• Funded by Gilead
• The overall objectives are:
• To collect around 5000 complete

integrase resistance instances

• Complete data instances are rewarded

To analyse data for several scientific studies:

• 1. Clinical and virological factors associated with virological
• utcomes of InSTI-containing therapies.
• 2. Prevalence of transmitted resistance to InSTIs and to other

classes and its influence on InSTI treatment outcomes.

• 3. Durability - comparison of time to InSTI discontinuation due to

side effects or drug-drug interactions using the different InSTI- based regimens, in naïve patients since 2015.

• 4. Reasons for RAL, EVG or DTG based discontinuation (for any

reason), in naïve patients since 2015.

• 5. Prevalence of resistance to InSTI and to companion drugs in (I)

patients failing InSTI-based first-line regimens, (II) patients switching to InSTIs while virologically suppressed and (III) treatment experienced patients starting InSTI with VL> 200 copies/ mL.

• 6. Efficacy and durability of combinations used in clinical practice

and not fully tested in clinical trials.

• The first round of data collection completed
• Preliminary results presented at EACS 2017

in Milan.

• Project presented at the International HIV

resistance workshop in Johannesburg, SA.

• Second round of data collection ongoing
• New collaborations in progress: with

individual centres and with RESPOND (collecting clinical data from INSTI treated patients)

• 14,420 INSTI therapies collected in the EIDB
• 2,794 standard datums (SDs) (1532 since 2012)
• 777 SDs from previously drug-naïve pat. (687 since

2012)

• 1,066 SDs from antiretroviral pretreated but INSTI-

naïve pat. (369 since 2012)

• 951 SDs from 620 INSTI-experienced pat. (398 since

2012)

• Out of which 109 failures (67 pat.)(VL>200 cp/ml at

>6 months from treatment start) (78 since 2012).

109 842 777 1066

collected standard datums

INSTI-experienced failures INSTI-experienced not failing drug-naïve ART experienced INSTI-naïve

• INTEGRATE NGS standardisation group
• Led by Martin Obermeier and Marc Noguera (Irsicaixa)
• Aiming at defining standard format for HIV NGS data

exchange and storage in integrated (INTEGRATE) databases – linked with the international “Winnipeg group”

• A survey has been launched on HIV NGS data

generation, analysis, collection. PARTICIPATE AT: https://www.euresist.org/integrate-ngs-survey

NGS

EuResist-Africa Network

Multinational data collection on the features

• f second-line ART failure in SSA

Objectives 1) to describe the characteristics and the determinants of virological failure to second-line ART in Sub-Saharan African adult (age > = 18 y.o.) patients 2) to calculate the incidence of second-line failure 3) to identify causes of second-line treatment failure

EuResist-Africa Network

CARE project: Common Action against

HIV/TB/HCV across the Regions of Europe

H2020 call: Research on HIV, TB, HCV in patients with mono-, co-infections and/ or comorbidities in the context of fostering collaboration with the Russian Federation

CARE project: Common Action against HIV/TB/HCV across the Regions of Europe

PARTICIPANT ORGANISATION NAME COUNTRY 1

EuResist Network (coordinator) (EuResist) Italy

2

REGIONH (CHIP) Denmark

3

Karolinska Institutet (KI) Sweden

4

University of Siena (UniSiena) Italy

5

University of Tubingen Germany

6

Forschungszentrum Borstel (FZB) Germany

7

Phtisiopneumology Institute Moldova

8

Imperial College UK

9

Vilnius University Clinic Lithuania

10

Public Health Center of the Ministry of Health Ukraine

11

Infectious Diseases, AIDS and Clinical research centre Georgia

CARE project: Common Action against HIV/TB/HCV across the Regions of Europe

PARTICIPANT ORGANISATION NAME COUNTRY

12 Gamaleya

Federal research centre for epidemiology and microbiology of the Ministry of health of Russia Russian Federation Moscow regional Center for the Prevention and Control of AIDS and Infectious Diseases Russian Federation

• St. Petersburg University

Russian Federation Krasnodar Territory Clinical Centre for Prevention and Control of AIDS Russian Federation Far East Center for prevention and control of AIDS and infectious diseases, Vladivostok Russian Federation Northern State Medical University in Arkhangelsk Russian Federation

20

http:/ / w w w .euresist.org http:/ / engine.euresist.org Contact: f.incardona@inform acro.info

Thank

Anders Sonnerborg Andrea De Luca Maurizio Zazzi Rolf Kaiser Thomas Lengauer Antonia Bezenchek Claudia Müller Joachim Büch Martin Obermeier Matthias Doering Michael Böhm Simon Lennartz

You